NCT00928525 - Imatinib in Patients With Desmoid Tumor and Chondrosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Advanced Desmoid TumorAdvanced Chondrosarcoma

Interventions

DRUG

Imatinib Mesylate

800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months

Trial Locations (7)

I.R.C.C. - Unit of Medical Oncology, Candiolo

Ospedale Gradenigo - Unit of Medical Oncology, Torino

Istituto Nazionale Tumori - Unit of Medical Oncology, Milan

Centro di Riferimento Oncologico - Unit of Medical Oncology, Aviano

Istituti Ortopedici Rizzoli - Unit of chemotherapy of Muscoloskeletal Tumors, Bologna

Policlinico S.Orsola Malpighi - Unit of Medical Oncology, Bologna

Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I, Roma

All Listed Sponsors

lead

Italian Sarcoma Group

NETWORK